Found 4 matching trials
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
PHASE2The goal of the Phase 1 study was to find the recommended Phase 2 dose of t...
Location
The University of Arizona Cancer Center
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
PHASE1Open label, phase Ib study of intratumoral tilsotolimod in combination with...
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
PHASE2A Phase 2 study intended to see efficacy of tilsotolimod in combination wit...
Status
Active Not Recruiting
Location
Banner University Medical Center Tucson Campus
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
PHASE3A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced me...
Location
University of Alabama at Birmingham (UAB)